LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects
In a 12‑month follow‑up of patients with anxiety related to life‑threatening disease, medically supervised LSD‑assisted psychotherapy produced sustained reductions in anxiety and improved quality of life with no lasting adverse reactions. Qualitative analysis suggests these benefits arose from facilitated emotional access, cathartic and peak experiences, interpersonal insights and a lasting restructuring of outlook and habits.
Authors
- Kirchner, K.
Published
Abstract
Objective: A recently published study showed the safety and efficacy of LSD-assisted psychotherapy in patients with anxiety associated with life-threatening diseases. Participants of this study were included in a prospective follow-up. Method: 12 months after finishing LSD psychotherapy, 10 participants were tested for anxiety (STAI) and participated in a semi-structured interview. A Qualitative Content Analysis (QCA) was carried out on the interviews to elaborate about LSD effects and lasting psychological changes. Results: None of the participants reported lasting adverse reactions. The significant benefits as measured with the STAI were sustained over a 12-month period. In the QCA participants consistently reported insightful, cathartic and interpersonal experiences, accompanied by a reduction in anxiety (77.8%) and a rise in quality of life (66.7%). Evaluations of subjective experiences suggest facilitated access to emotions, confrontation of previously unknown anxieties, worries, resources and intense emotional peak experiences à la Maslow as major psychological working mechanisms. The experiences created led to a restructuring of the person’s emotional trust, situational understanding, habits and world view. Conclusions: LSD administered in a medically supervised psychotherapeutic setting can be safe and generate lasting benefits in patients with a life-threatening disease. Explanatory models for the therapeutic effects of LSD warrant further study.
Research Summary of 'LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects'
Introduction
Gasser and colleagues place this study in the context of a long history of using mind-altering substances for healing and existential concerns, noting that LSD was widely studied after its discovery in 1943 for conditions including anxiety and end‑of‑life distress. The introduction summarises prior reports that LSD can intensify affectivity, broaden associations and weaken ego boundaries, and highlights a contemporary clinical gap: psychological care for patients facing life‑threatening illness remains inadequate and alternative approaches warrant evaluation. This paper reports a long‑term follow‑up (LTFU) of patients who took part in a Phase II, double‑blind, active placebo‑controlled randomized trial of LSD‑assisted psychotherapy for anxiety related to life‑threatening disease. The stated aim here is twofold: to assess whether reductions in anxiety observed in the original trial were sustained at 12 months, and to explore participants’ subjective acute and lasting experiences using semi‑structured qualitative interviews analysed by Qualitative Content Analysis (QCA). The investigators thereby combine quantitative anxiety measures with a detailed, client‑centred qualitative exploration of psychological change and potential therapeutic mechanisms.
Methods
The LTFU was implemented as an amendment to a Phase II randomised clinical trial that had received ethics and regulatory approvals in Switzerland and an FDA IND. The initial trial was double‑blind and active placebo‑controlled; participants underwent a preparatory psychotherapy phase followed by two guided drug‑assisted sessions. For the active intervention, a full dose of LSD 200 µg p.o. was selected, with an active placebo of LSD 20 µg used in the control arm. Two therapists guided each drug session (8–10 hours) using music, brief interpersonal interventions and an overnight stay in the physician's office, followed by an integrative debrief the next morning. The preparatory period comprised 6–8 psychotherapy sessions over about three months to establish therapeutic rapport; the two LSD sessions were delivered 4–6 weeks apart. Participant flow as reported in the extracted text: twelve people entered the initial study and were randomised to full‑dose (N=8) or active‑placebo (N=4). Crossover to full dose was offered after unblinding; one participant chose not to crossover and another died during follow‑up. Ten participants qualified for the LTFU; specifics for analysis differed by measure (see Results). The investigators do not report additional inclusion/exclusion criteria in the extracted text beyond those described elsewhere in the original study. Outcome measures for the LTFU combined quantitative and qualitative methods. The primary quantitative instrument was the Spielberger State and Trait Anxiety Inventory (STAI) Form X; STAI assesses both transient (state) and enduring (trait) anxiety. For qualitative assessment, semi‑structured interviews (conducted at participants’ homes or by telephone) addressed subjective experiences, changes in daily life, quality of life, anxiety, attitudes and values. Interviews were audio‑recorded and transcribed where participants consented. The researchers applied Qualitative Content Analysis (QCA) to reduce and categorise interview material systematically, using MAXQDA software to assign transcript segments to categories. Statistical analysis of STAI scores used repeated measures analysis of variance (ANOVA) with time as a within‑subject factor (levels: baseline, end of study, follow‑up) and Tukey post hoc comparisons when main effects of time were significant. The extracted text does not provide additional details on handling of missing data or other modelling choices beyond this.
Results
Quantitative outcomes: Nine participants who received two full doses of LSD 200 µg were evaluated on the STAI. Repeated measures ANOVA showed a significant main effect of time for STAI state scores (reported as F(2,16)=15.7, p=0.0002), with Tukey post hoc tests indicating significant reductions from baseline to end of study (p=0.0008) and baseline to 12‑month follow‑up (p=0.0005). For STAI trait scores the main effect of time was also significant (reported as F(2,16)=9.5, p=0.002), with post hoc reductions at end of study (p=0.006) and at follow‑up (p=0.004). The authors report that STAI state and trait scores did not rise after the end of the study, indicating maintenance of the anxiolytic effect over 12 months. No lasting adverse reactions were reported by participants in the quantitative assessments. Qualitative findings: Semi‑structured interviews were analysed using QCA. The interviews (reported as conducted with nine participating subjects) indicated that all participants described benefits from LSD‑assisted psychotherapy. Key summary statistics from the interview analysis were: 77.8% reported sustained reductions in anxiety, 77.9% reported less fear of death and 66.7% reported improved quality of life. Thematic analysis identified several recurrent domains of experience: facilitated access to emotions and catharsis (intensified affect leading to emotional processing), de‑schematising and altered perspectives (seeing self and situations from novel vantage points), marked changes in basic emotional tone during sessions (some participants moved from intense fear or pain to states of relaxation, love or ‘‘light’’), long‑term shifts in perspectives, attitudes and values (including reprioritisation toward family and meaning), and increases in aspects of quality of life such as reduced suicidal ideation, calmer affect, improved sleep and greater patience. Adverse and subacute effects: No participant reported sustained negative effects attributable to LSD. Transient difficulties during sessions were described by some (intense emotions, initial distrust, temporary destabilisation or tiredness for a few days afterwards). A few participants reported short‑term post‑session tiredness or a sense of being ‘‘stirred’’ for a day or two. No flashbacks or long‑term harms were reported at 12 months. Anecdotal observations included two participants with prior migraine reporting reductions in migraine frequency after treatment, but these were incidental and not systematically assessed. Other outcomes: The researchers note that three participants had died a few months after the LTFU period, reflecting the severe somatic illness burden in the sample. Beyond individual quotations selected to illustrate core themes, the extracted text does not present further quantitative effect sizes or subgroup analyses.
Discussion
Gasser and colleagues interpret their findings as evidence that anxiety reductions achieved during a three‑month course of LSD‑assisted psychotherapy were stable at 12 months. The authors emphasise that observed improvements in STAI trait scores were corroborated by participants’ subjective reports of enhanced relaxation, equanimity, self‑assurance and mental strength—dimensions not captured by the original pathology‑focused measures. They identify emotional peak experiences—transitions from intense negative affect to states of relaxation, awe or love—as central therapeutic moments that contributed to lasting psychological change. The discussion frames possible mechanisms at psychological and neurobiological levels. Psychologically, the investigators propose a combination of processes including facilitated access to emotions, abreaction and catharsis, cognitive reframing and psychodynamic material emerging into consciousness; they highlight ‘‘peak’’ or ‘‘Maslow‑style’’ experiences that may restructure self‑concept and reduce rumination. Neurobiologically, the authors speculate—drawing on literature on indolealkylamine hallucinogens—that action at 5‑HT2A receptors, modulation of prefrontal and thalamic circuits, changes in functional connectivity (including default‑mode network alteration) and downstream effects such as increased glutamatergic activity or BDNF expression might underlie enhanced cognitive flexibility and sustained psychological change. These mechanistic accounts are explicitly presented as hypothetical and warranting further research. The authors acknowledge limitations: the small sample size in the LTFU (N=10 qualified; analyses involved nine participants for some measures), the lack of a contemporaneous control group in follow‑up because of the crossover design and ethical constraints, and limited neurobiological data. They also note that the moderate LSD dose used (200 µg) may have produced ‘‘incomplete’’ mystical experiences compared with higher typical psychedelic doses, which could explain differences with historical reports where a subgroup of patients experienced dramatic remission. Finally, the discussion addresses safety, stating that when delivered with appropriate dose and setting, the sessions produced only transient adverse reactions for some participants and no serious or lasting harms at 12 months. The authors call for further systematic research on explanatory models, pre/post neuroimaging, and larger samples to clarify mechanisms and generalisability.
Conclusion
The study concludes that LSD‑assisted psychotherapy delivered in a medically supervised psychotherapeutic setting was safe in this small sample of patients with life‑threatening disease and was associated with sustained reductions in anxiety at 12 months. Qualitative analysis suggests that cognitive, psychodynamic and particularly emotional ‘‘peak’’ experiences contributed to enduring psychological change, including improved coping, reprioritisation of values and enhanced quality of life. No serious adverse effects were reported, and the authors recommend further systematic investigation of therapeutic mechanisms and longer‑term outcomes.
View full paper sections
RESULTS
We used repeated measurement analysis of variance (ANOVA) to analyse changes in the STAI scores over time using time as within-subject factor (levels: baseline, end of study, and followup) followed by Tukey post hoc tests based on significant main effects of time.
CONCLUSION
The present study has shown that psychological improvement as achieved during 3 months of LSD-assisted psychotherapy is stable over a 12-month period. The condition of the patients was serious in that they were facing a life-threatening illness and the anticipation of possible death. The results from the QCA suggest that the improvement (as demonstrated by the significantly lower STAI trait scores) is also perceived as valid in personal statements (Table). Interestingly, the improvement in psychopathological symptoms was accompanied by positive psychological changes in the subjects (e.g. increases in relaxation, equanimity, self-assurance, mental strength), which we were not able to detect in the original study due to the focus on pathologyoriented measures. One important distinction that has to be made at this point is about the paradigms of psycholytic therapy (low-dose serial sessions in a psychoanalytic frame for treating neuroses) and psychedelic therapy (one or two high-dose sessions directed to mystical peak experiences to initiate a personality change). Even if the typical dose in typical psychedelic therapy sessions (200-500 mcg LSD;is somewhat higher and the setting more structured (e.g. music played throughout), the present study is in some major components equivalent to the psychedelic approach, but did allow for more cognitive, psychodynamic and interpersonal aspects. Up to now, only the psychedelic approach was used in treatment of en-of-life anxiety (e.g.. A typical psychological reaction to a life-threatening disease is an anxiety/depression-driven tendency for interpersonal isolation and the attempt to harden oneself against the threat triggered by the anticipation of severe suffering and possible death. As studies in the past, as well as the present study, have shown, this situation appears to be essentially changed by the effects of treatment with LSD. Unfortunately, there is not much knowledge about the effects of LSD-like hallucinogens in psychotherapy, especially at a neurobiological level. We will give an outline of some ideas relating to possible mechanisms of action in the following paragraphs.
Study Details
- Study Typeindividual
- Populationhumans
- Characteristicsfollow upinterviewsqualitative
- Journal
- Compounds
- Topic
References (19)
Papers cited by this study that are also in Blossom
Carhart-Harris, R. L., Friston, K. J. · Brain (2010)
Carhart-Harris, R. L., Colasanti, A., Erritzoe, D. et al. · PNAS (2012)
Carhart-Harris, R. L., Chialvo, D. R., Feilding, A. et al. · Frontiers in Human Neuroscience (2014)
Abbasi, N., Bargiotas, T., Carhart-Harris, R. L. et al. · British Journal of Psychiatry (2018)
Cohen, S. · Journal of Nervous and Mental Disease (1980)
Griffiths, R. R., Jesse, R., McCann, U. D. et al. · Journal of Psychopharmacology (2006)
Chopra, G. S., Danforth, A. L., Greer, G. R. et al. · JAMA Psychiatry (2011)
Goodman, L. E., Grof, S., Richards, W. A. · Pharmacopsychiatry (1973)
Geyer, M. A., Halberstadt, A. L. · Neuropharmacology (2011)
Kast, E. · Psychiatric Quarterly (1967)
Show all 19 referencesShow fewer
Kurland, A. A. · Journal of Psychoactive Drugs (1985)
Griffiths, R. R., Johnson, M. W., MacLean, K. A. · Journal of Psychopharmacology (2011)
Pahnke, W. N. · Psychedelic Review (1969)
Emrich, H. M., Halpern, J. H., Hintzen, A. et al. · CNS Neuroscience and Therapeutics (2008)
Dileo, F. B., Rhead, J. C., Richards, W. A. et al. · Journal of Psychedelic Drugs (2012)
Halpern, J. H., Pope Jr, H. G., Sewell, R. A. · Neurology (2006)
Kometer, M., Vollenweider, F. X. · Nature Reviews Neuroscience (2010)
Angst, J., Leenders, K. L., Maguire, P. et al. · Neuropsychopharmacology (1997)
Bäbler, A., Hell, D., Vogel, H. et al. · NeuroReport (1998)
Cited By (154)
Papers in Blossom that reference this study
Calderon, J. R., Effinger, D. P., King, J. L. et al. · ACS Pharmacology and Translational Science (2025)
Hawrot, T., Mueller, F., Schmid, Y. · Neuroscience Applied (2025)
Adams, M., Blest-Hopley, G., Busch, C. et al. · Brain and Behavior (2025)
Aicher, H. D., Dornbierer, D. A., Meling, D. et al. · Journal of Psychopharmacology (2025)
Andersen, T. L., Falck, N., Fisher, P. M. et al. · MedRvix (2025)
Garcia-Romeu, A., Jackson, H., Johnson, M. W. et al. · Journal of Psychedelic Drugs (2025)
Calder, A. E., Hasler, G., Holze, F. et al. · Journal of Psychopharmacology (2024)
Caspani, G., Jefferies, W. A., Netzband, N. et al. · Pharmacological Research (2024)
Corlett, P. R., Doss, M. K., Grimmer, H. J. et al. · Communications Psychology (2024)
Capper, M. J., Cunningham, M. J., Duggan, P. et al. · Nature (2024)
Show all 154 papersShow fewer
Bayes, A., Brett, J., Haldane, K. et al. · Neuroscience and Biobehavioral Reviews (2024)
Agin-Liebes, G. I., Bogenschutz, M. P., Haas, A. et al. · Psychology of Addictive Behaviors (2024)
Beller, N., Campbell, W. K., Erritzoe, D. et al. · Journal of Psychedelic Studies (2023)
Jacobs, E., Murphy-Beiner, A., Nutt, D. J. et al. · Neuroethics (2023)
Duerler, P., Gubser, L. P., Lewis, C. R. et al. · Scientific Reports (2023)
Acar, K., Cabrera, A. E., Horntvedt, O. et al. · Scientific Reports (2023)
Carhart-Harris, R. L., Chiacchiaretta, P., Ferretti, A. et al. · Biological Psychiatry (2023)
Adamska, I., Finc, K. · Psychopharmacology (2023)
Arikci, D., Becker, A. M., Coviello, F. et al. · Neuropsychopharmacology (2023)
Aggerwal, S., Deol, J. K., Di Virgilio, V. et al. · MedRvix (2023)
Bright, S. J., Bruno, R., Sharbanee, J. M. et al. · Journal of Humanistic Psychology (2023)
Ferris, J. A., Kopra, E., Kuypers, K. P. C. et al. · Journal of Psychopharmacology (2023)
Calder, A. E., Hasler, G., Oehen, P. et al. · Journal of Psychopharmacology (2023)
Aggerwal, S., Deol, J. K., Di Virgilio, A. et al. · MedRvix (2023)
Carhart-Harris, R. L., Damiani, G., Deckersbach, T. et al. · PLOS ONE (2023)
Dolder, P. C., Gasser, P., Holze, F. et al. · Biological Psychiatry (2023)
Aaronson, S. T., Kirlic, N., Lennard-Jones, M. et al. · Journal of Affective Disorders (2023)
Areesanan, A., Gründemann, C., Liechti, M. E. et al. · Frontiers in Psychiatry (2023)
Anand, A., Barnett, B. S., Dewey, E. N. et al. · MedRvix (2022)
Karlawish, J., Largent, E. A., Lynch, H. F. et al. · AJOB Neuroscience (2022)
Bedford, P., Borgwardt, S., Diaconescu, A. O. et al. · Neuropsychopharmacology (2022)
Barros-Álvarez, X., Che, T., Confair, D. N. et al. · Nature (2022)
Calder, A. E., Hasler, G. · Neuropsychopharmacology (2022)
Dourron, H. M., Hendricks, P. S., Strauss, C. · Pharmacological Reviews (2022)
Breeksema, J. J., Kamphuis, J., Schoevers, R. A. et al. · Journal of Psychopharmacology (2022)
Carhart-Harris, R. L., Erritzoe, D., Haijen, E. et al. · Journal of Psychopharmacology (2022)
Bernhardt, B., Carhart-Harris, R. L., Girn, M. et al. · NeuroImage (2022)
Aaru, J., Kaup, K. K., Pikame, J. et al. · Frontiers in Psychiatry (2022)
Amada, N., Shane, J. · Journal of Humanistic Psychology (2022)
Belser, A. B. · Frontiers in Psychology (2022)
Forstmann, M., Sagioglou, C. · European Psychologist (2022)
Baker-Jones, M., Carhart-Harris, R. L., Erritzoe, D. et al. · Frontiers in Pharmacology (2022)
Comai, S., De Gregorio, D., Enns, J. P. et al. · Neuropsychopharmacology (2022)
Family, N., Hendricks, P. S., Krediet, E. et al. · Journal of Psychopharmacology (2022)
Duthaler, U., Eckert, A., Holze, F. et al. · Neuropsychopharmacology (2022)
Davis, A. K., Lancelotta, R., Mason, N. L. et al. · Journal of Neurochemistry (2022)
Araújo, D. B., Daldegan-Bueno, D., Falchi, M. et al. · Journal of Psychopharmacology (2022)
Becker, A. M., Borgwardt, S., Holze, F. et al. · Psychopharmacology (2022)
Carhart-Harris, R. L., Kettner, H., Lyons, T. et al. · Journal of Psychopharmacology (2022)
Clarke, G., Gillan, C. M., Harkin, A. et al. · Frontiers in Psychiatry (2021)
Johnson, M. W., Strickland, J. C. · Advances in Pharmacology (2021)
Araújo, D. B., Feilding, A., Maia, L. O. et al. · Psychopharmacology (2021)
Betzler, F., Gründer, G., Johnson, M. W. et al. · Current Addiction Reports (2021)
Caluori, T. V., Holze, F., Liechti, M. E. et al. · Psychopharmacology (2021)
Castelhano, J. M., Castelo-Branco, M., Lima, G. M. et al. · Frontiers in Pharmacology (2021)
Chiu, Y-T., Means, C. R., Nadkarni, V. et al. · Scientific Reports (2021)
Álvarez, E., Domínguez-Clavé, E., Elices, M. et al. · Human Psychopharmacology (2021)
Dollar, C. B. · Qualitative Criminology (2021)
Falchi, M., Feilding, A., Palhano-Fontes, F. et al. · Psychological Medicine (2021)
Carhart-Harris, R. L., Kettner, H., Letheby, C. et al. · Scientific Reports (2021)
Luke, D., Michael, P., Robinson, O. · Frontiers in Psychology (2021)
Adams, C., Carhart-Harris, R. L., Douglass, H. et al. · Journal of Psychopharmacology (2021)
Dolder, P. C., Holze, F., Liechti, M. E. et al. · Scientific Reports (2021)
Carhart-Harris, R. L., Doblin, R., Ginsberg, N. et al. · Frontiers in Pharmacology (2021)
Campbell, W. K., Carter, N. T., Miller, J. D. et al. · Scientific Reports (2021)
Breslow, L., Singhal, N., Weissman, C. R. et al. · ACS Pharmacology and Translational Science (2021)
de Manicor, M., Galvão-Coelho, N. L., Gonzales, M. et al. · Psychopharmacology (2021)
Barrett, F. S., Davis, A. K., Griffiths, R. R. et al. · Journal of Psychopharmacology (2021)
Johnson, M. W., Nayak, S. · Pharmacopsychiatry (2020)
Nichols, D. E., Walter, H. · Pharmacopsychiatry (2020)
Daldegan-Bueno, D., Maia, L. O., Tófoli, L.F. · Journal of Psychoactive Drugs (2020)
Dolder, P. C., Feilding, A., Holze, F. et al. · European Neuropsychopharmacology (2020)
Aguilar-Valles, A., De Gregorio, D., Gobbi, G. et al. · Journal of Neuroscience (2020)
Borgwardt, S., Dolder, P. C., Holze, F. et al. · Neuropsychopharmacology (2020)
Brouwer, A., Carhart-Harris, R. L. · Journal of Psychopharmacology (2020)
Borgwardt, S., Holze, F., Lang, U. E. et al. · Frontiers in Psychiatry (2020)
Gasser, P., Liechti, M. E., Oehen, P. et al. · Journal of Psychopharmacology (2020)
Che, T., DiBerto, J. F., Kim, K. et al. · Cell (2020)
Breeksema, J. J., Krediet, E., Niemeijer, A. R. et al. · CNS Drugs (2020)
Hausen, A., Kangaslampi, S., Rauteenmaa, T. · Journal of Psychoactive Drugs (2020)
Greif, A., Šurkala, M. · Medicine Health Care and Philosophy (2020)
Bornemann, J. · Journal of Psychoactive Drugs (2020)
Clifton, J. M., Davis, A. K., Griffiths, R. R. et al. · Journal of Psychopharmacology (2020)
Sisti, D., Smith, W. R. · Journal of Medical Ethics (2020)
Chi, T., Gold, J. A. · Journal of the Neurological Sciences (2020)
Dwyer, J., Hubik, D. J., O Callaghan, C. et al. · Journal of Music Therapy (2020)
Aday, J. S., Bloesch, E. K., Davis, A. K. et al. · Neuroscience and Biobehavioral Reviews (2020)
Benko, J., Vranková, S. · Molecules (2020)
Betzler, F., Evens, R., Gründer, G. et al. · Frontiers in Psychiatry (2020)
Elices, M., Farré, M., Fonseca, F. et al. · Frontiers in Psychiatry (2020)
Agin-Liebes, G. I., Bossis, A. P., Fischer, S. et al. · Journal of Psychopharmacology (2020)
Haden, M., Woods, B. · Journal of Studies on Alcohol and Drugs (2020)
Sartori, S. B., Singewald, N. · Pharmacology and Therapeutics (2019)
Borgwardt, S., Duerig, R., Eckert, A. et al. · Neuropsychopharmacology (2019)
Felix, M., Stefan, B. · Swiss Medical Weekly (2019)
Argento, E., Capler, R., Lucas, P. et al. · Drugs and Alcohol Review (2019)
Carhart-Harris, R. L., Haijen, E. C. H. M., Idialu-Ikato, K. et al. · Journal of Psychopharmacology (2019)
Duthaler, U., Hoener, M. C., Krähenbühl, S. et al. · Biochemical Pharmacology (2019)
Nutt, D. J. · Dialogues in Clinical Neuroscience (2019)
Borgwardt, S., Duthaler, U., Holze, F. et al. · British Journal of Clinical Pharmacology (2019)
Fadiman, J., Korb, S. · Journal of Psychoactive Drugs (2019)
Barone, W., Beck, J., Mitsunaga-Whitten, M. et al. · Journal of Psychoactive Drugs (2019)
Cassol, H., Charland-Verville, V, Erowid, E., Erowid, F. et al. · Consciousness and Cognition (2019)
Polito, V., Stevenson, R. J. · PLOS ONE (2019)
Carhart-Harris, R. L., Demetriou, L., Nutt, D. J. et al. · Neuropharmacology (2018)
Hendricks, P. S. · International Review of Psychiatry (2018)
Bouso, J. C., Dos Santos, R. G., Hallak, J. E. · Expert Review of Clinical Pharmacology (2018)
Carhart-Harris, R. L., Cassol, H., Erritzoe, D. et al. · Frontiers in Psychology (2018)
Ross, S. · International Review of Psychiatry (2018)
Glasser, C., Neitzke-Spruill, L. · Journal of Psychoactive Drugs (2018)
Schenberg, E. E. · Frontiers in Pharmacology (2018)
Aicher, H., Jungaberle, H., Rougemont-Bücking, A. et al. · Neuropharmacology (2018)
Carhart-Harris, R. L., Erritzoe, D., Kaelen, M. et al. · Acta Psychiatrica Scandinavica (2018)
Barnett, B. S., Pope Jr, H. G., Siu, W. O. · Journal of Nervous and Mental Disease (2018)
Bird, B. M., Lafrance, A., Thiessen, M. S. et al. · Journal of Psychopharmacology (2018)
D’Souza, D. C., Schindler, E. A. D., Sloshower, J. A. et al. · Frontiers in Pharmacology (2018)
Nichols, D. E. · ACS Chemical Neuroscience (2018)
Grob, C. S., Nichols, D. E. · Forensic Science International (2018)
Gasser, P., Gutwinski, S., Hermle, L. et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry (2018)
Carhart-Harris, R. L., Nutt, D. J., Roseman, L. · Frontiers in Pharmacology (2018)
Iliff, J., Nutt, D. J., Rucker, J. · Neuropharmacology (2017)
Aicher, H., Bosch, O. G., Kraehenmann, R. et al. · Frontiers in Pharmacology (2017)
Borgwardt, S., Dolder, P. C., Lang, U. E. et al. · Acta Psychiatrica Scandinavica (2017)
Liechti, M. E., Schmid, Y. · Psychopharmacology (2017)
Bøhling, F. · International Journal of Drug Policy (2017)
Carhart-Harris, R. L., Nutt, D. J. · Journal of Psychopharmacology (2017)
Carhart-Harris, R. L., Day, C. M., Krzanowski, J. et al. · Journal of Humanistic Psychology (2017)
Kraehenmann, R. · Current Neuropharmacology (2017)
Agin-Liebes, G. I., Belser, A. B., Bossis, A. P. et al. · Journal of Humanistic Psychology (2017)
Agin-Liebes, G. I., Belser, A. B., Bossis, A. P. et al. · Journal of Humanistic Psychology (2017)
Liechti, M. E. · Neuropsychopharmacology (2017)
Borgwardt, S., Dolder, P. C., Harder, S. et al. · Translational Psychiatry (2017)
Kaelen, M. · Imperial College London (2017)
Dolder, P. C., Hammann, F., Kraemer, T. et al. · Clinical Pharmacokinetics (2017)
Franciotti, K. J., Halpern, J. H., Holden, S. C. et al. · Journal of Psychopharmacology (2017)
Betz, R. M., Che, T., Dror, R. O. et al. · Cell (2017)
Martin, D. A., Nichols, C. D. · Current Topics in Behavioral Neurosciences (2017)
Preller, K. H., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Flynn, S., Frowde, K. D., Jelen, L. A. et al. · Journal of Psychopharmacology (2016)
Hartogsohn, I. · Journal of Psychopharmacology (2016)
Johnson, M. W., Nichols, C. D., Nichols, D. E. · Clinical Pharmacology and Therapeutics (2016)
Crippa, J. A., Dos Santos, R. G., Hallak, J. E. et al. · Neuroscience and Biobehavioral Reviews (2016)
Dolder, P. C., Liechti, M. E., Schmid, Y. · Psychopharmacology (2016)
Borgwardt, S., Dolder, P. C., Liechti, M. E. et al. · Neuropsychopharmacology (2016)
Carhart-Harris, R. L., Feilding, A., Kaelen, M. et al. · Human Brain Mapping (2016)
Kraehenmann, R., Pokorny, T., Preller, K. H. et al. · European Neuropsychopharmacology (2016)
Nichols, D. E. · Pharmacological Reviews (2016)
Crippa, J. A., Dos Santos, R. G., Hallak, J. E. et al. · Therapeutic Advances in Psychopharmacology (2016)
Álvarez, E., de la Fuente Revenga, M., Domínguez-Clavé, E. et al. · Brain Research Bulletin (2016)
Crippa, J. A., Dos Santos, R. G., Hallak, J. E. et al. · brazilian Journal of Psychiatry (2016)
McKenna, D., Riba, J. · Current Topics in Behavioral Neurosciences (2016)
Kometer, M., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Johnson, M. W., Tupper, K. W., Wood, E. et al. · Canadian Medical Association Journal (2015)
Barrett, F. S., Bolstridge, M., Carhart-Harris, R. L. et al. · Psychopharmacology (2015)